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Abstract 
Parkinson’s disease dementia  is neuropathologically characterized by aggregates of α‑synuclein (Lewy bodies) in 
limbic and neocortical areas of the brain with additional involvement of Alzheimer’s disease‑type pathology. Whilst 
immune activation is well‑described in Parkinson’s disease (PD), how it links to protein aggregation and its role in PD 
dementia has not been explored. We hypothesized that neuroinflammatory processes are a critical contributor to 
the pathology of PDD. To address this hypothesis, we examined 7 brain regions at postmortem from 17 PD patients 
with no dementia (PDND), 11 patients with PD dementia (PDD), and 14 age and sex‑matched neurologically healthy 
controls. Digital quantification after immunohistochemical staining showed a significant increase in the severity of 
α‑synuclein pathology in the hippocampus, entorhinal and occipitotemporal cortex of PDD compared to PDND cases. 
In contrast, there was no difference in either tau or amyloid‑β pathology between the groups in any of the examined 
regions. Importantly, we found an increase in activated microglia in the amygdala of demented PD brains compared 
to controls which correlated significantly with the extent of α‑synuclein pathology in this region. Significant infiltra‑
tion of  CD4+ T lymphocytes into the brain parenchyma was commonly observed in PDND and PDD cases compared 
to controls, in both the substantia nigra and the amygdala. Amongst PDND/PDD cases,  CD4+ T cell counts in the 
amygdala correlated with activated microglia, α‑synuclein and tau pathology. Upregulation of the pro‑inflammatory 
cytokine interleukin 1β was also evident in the substantia nigra as well as the frontal cortex in PDND/PDD versus 
controls with a concomitant upregulation in Toll‑like receptor 4 (TLR4) in these regions, as well as the amygdala. The 
evidence presented in this study show an increased immune response in limbic and cortical brain regions, includ‑
ing increased microglial activation, infiltration of T lymphocytes, upregulation of pro‑inflammatory cytokines and TLR 
gene expression, which has not been previously reported in the postmortem PDD brain.
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Introduction
The development of dementia is a key milestone in the 
progression of Parkinson’s disease (PD). Almost half of 
patients develop PD dementia (PDD) within 10  years 
from diagnosis [76], reaching over 80% at 20 years [29]. 
Widespread cortical and limbic Lewy body deposition 
has been reported by several clinicopathological studies 
to be the best pathological correlate of cognitive decline 
in PD [1, 30, 34, 38, 47, 51]. However, the association 
between cortical Lewy body pathology and PD dementia 
is far from clear-cut, given that approximately one-third 
of PD cases classified as Braak PD Stage 3 (indicative of 
no neocortical Lewy bodies) were found to be demented 
during life [5]. Conversely, a number of PD cases exhib-
iting neocortical and/or limbic Lewy body pathology 
had no history of cognitive impairment [8, 60]. Other 
studies have reported a significant role for co-existing 
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Alzheimer’s type pathology [10, 27, 37, 39, 41, 64] and 
a combination of both cortical Lewy body and Alzhei-
mer’s-type pathologies has been suggested as a more 
robust correlate of PD dementia [9, 31]. Despite extensive 
research on the neuropathological substrate of PDD, a 
consensus has yet to be reached. These conflicting results 
may be in part due to differences in case selection, the 
methodologies used, as well as the inherent heterogene-
ity of the disease, however, it also suggests that mecha-
nisms other than protein aggregation may be critically 
contributing to cognitive decline in PD.
Neuroinflammation in the PD brain has been described 
in a small number of postmortem studies, as well as 
in vivo  using  [11C]PK11195 PET imaging [25], but clin-
icopathological studies assessing neuroinflammation in 
PD dementia cases are lacking. McGeer and colleagues 
were the first to report an increase in the number of 
HLA-DR+ microglia in the substantia nigra of PD com-
pared to healthy brains [52], while a subsequent study 
found increased numbers of microglia in the hippocam-
pus, transentorhinal, cingulate and temporal cortices of 
PD cases compared to controls [36]. Infiltration of both 
helper  (CD4+) and cytotoxic  (CD8+) T lymphocytes 
into the parenchyma of the substantia nigra has been 
observed in the vicinity of neuromelanin-positive dopa-
minergic neurons in the PD brain [6]. Upregulation of 
pro-inflammatory cytokines has also been reported in 
PD, including increased expression of tumour necrosis 
factor α (TNFα), interleukin 1β (IL-1β), and interferon γ 
(IFNγ) in the substantia nigra, and upregulation of inter-
leukin 6 (IL6) and interleukin 2 (IL2) in the striatum [33, 
55–57]. Pro-inflammatory cytokine expression has not 
been explored in more widespread brain regions.
A prominent pathway regulating inflammatory 
responses is mediated by Toll-like receptors (TLRs) [42]. 
Accumulating evidence suggests that α-synuclein may 
be triggering microglial activation via TLR2 and TLR4, 
leading to downstream secretion of pro-inflammatory 
mediators [13, 22, 44, 46]. Both these receptors have been 
found to be upregulated at the protein level in the cau-
date/putamen of postmortem PD cases compared to con-
trols [16], with TLR4 also being elevated in the substantia 
nigra [67] and TLR2 in the anterior cingulate cortex [19].
Hence, although there is accumulating evidence sug-
gesting that neuroinflammation is a feature of the pathol-
ogy of PD, investigation of neuroinflammatory processes 
in extra-nigral brain regions has been limited to date, 
and no studies have explored associations with cognitive 
status during life. We therefore sought to characterize 
inflammatory changes across multiple brain regions in 
demented compared to non-demented PD cases and age-
matched controls, in addition to better characterizing 
the anatomical pattern of misfolded protein pathology 
in these cases. We explored the relationship between 
markers of neuroinflammation and aberrant forms of 
α-synuclein, tau and amyloid-β, as well as the association 




This study received ethical approval from the London—
Bloomsbury Research Ethics Committee (16/LO/0508). 
Postmortem brain tissue from 28 idiopathic PD cases 
and 14 age and sex-matched controls with no known 
history of neurological or neuropsychiatric symptoms 
was acquired from the Queen’s Square Brain Bank and 
the Cambridge Brain Bank. Presence/absence of tau or 
amyloid-β pathology was not used as a selection crite-
rion for controls, as our aim was the comparison of PD 
cases with typical neurologically healthy aged individu-
als in whom a degree of incidental protein pathology is 
expected. Brains were bisected in the sagittal plane with 
one half flash-frozen and stored at − 80 °C and the other 
half fixed in 10% neutral buffered formalin for 2–3 weeks. 
From the formalin-fixed tissue, blocks were sampled and 
embedded in paraffin.
All PD cases had been assessed during life at the Par-
kinson’s Disease Research Clinic, University of Cam-
bridge, UK, with prospective collection of longitudinal 
clinical and neuropsychological data. All PD cases met 
the UK Parkinson’s Disease Society Brain Bank Diag-
nostic Criteria. Cause of death was determined based on 
the death certificate. Standardized assessments included 
the Unified Parkinson’s Disease Rating Scale (UPDRS), 
Hoehn and Yahr stage, the Mini-Mental State Examina-
tion (MMSE), and verbal fluency testing. PD dementia 
was diagnosed using MDS PD Dementia level 1 criteria 
[17, 21], operationalized using MMSE < 26, impaired cog-
nitive performance in more than 1 domain and impair-
ment in functional ability on activities of daily living as 
assessed by the clinician. In cases who were lost to fol-
low-up from the Parkinson’s Disease Research Clinic, 
dementia status was determined retrospectively through 
review of the medical notes.
Immunoperoxidase staining of human postmortem brain 
tissue
Immunohistochemistry was performed on 10  μm-thick 
paraffin-embedded sections from 7 brain regions: sub-
stantia nigra, amygdala, hippocampus, entorhinal, occipi-
totemporal, prefrontal, and posterior parietal cortex. One 
section per brain region was stained for each marker of 
interest in control and PD cases. Sections were deparaffi-
nized and sequentially rehydrated, in xylene, 100% EtOH, 
90% EtOH, 70% EtOH and  dH2O. Antigen retrieval was 
Page 3 of 19Kouli et al. acta neuropathol commun           (2020) 8:211  
performed in 98% formic acid (pH = 1.6–2.0) for 5  min 
(α-synuclein and tau), or in boiling 10  mM sodium cit-
rate buffer (0.05% Tween20, pH = 6) for 30 min (all other 
antibodies). Blocking of endogenous peroxidase activity 
was performed in 3%  H2O2 in PBS, for 15 min at room 
temperature. Sections were then incubated with blocking 
solution (2% milk for α-synuclein and tau, or 20% normal 
rabbit serum for all other antibodies) for 20 min at room 
temperature. Sections were subsequently incubated with 
the appropriate primary antibody for 1 h at room temper-
ature (α-synuclein [Enzo Life Sciences sa3400, 1:250]; tau 
[in house P11/57 clone, 1:5]; amyloid-β [DAKO MO872, 
1:100]; GFAP [DAKO Z0334, 1:500]; HLA-DR [DAKO 
MO775, 1:500]; Iba1 [Wako Chemicals 019-19741, 
1:4000]; CD3 [Leica Biosystems NCL-L-CD3-565, 1:300]; 
CD4 [Abcam ab133616, 1:100]; CD8 [Abcam ab17147, 
1:100]). Following 3 × 5  min washes with PBS, sections 
were incubated with biotinylated secondary antibody for 
30 min at room temperature. Following 3 × 5 min washes 
with PBS, the sections were incubated with ABC Elite 
Vectastain Kit (Vector Laboratories) for 30 min at room 
temperature. Colour was developed by 4 min incubation 
in DAB Peroxidase Substrate solution (Vector Laborato-
ries). Upon rinsing with  dH2O, sections were counter-
stained with Harris’ Haematoxylin for 30  s, sequentially 
dehydrated in ascending EtOH concentrations and cov-
erslipped using DPX mounting medium. Slide scanning 
was done at the Histopathology/HIS facility at the Can-
cer Research UK Cambridge Institute. Scanning was per-
formed on the Aperio Scanscope AT2 (Leica Biosystems) 
at ×20 magnification with a resolution of 0.503 μm per 
pixel. Images were viewed with the Aperio Imagescope 
viewing platform (Leica Biosystems).
Neuropathological assessment
The diagnosis of idiopathic PD was confirmed by the 
presence of Lewy bodies in the substantia nigra. Neu-
ropathological assessment of α-synuclein, tau, and 
amyloid-β was performed using Aperio ImageScope soft-
ware. Lewy body, neurofibrillary tau tangle and amyloid-β 
pathology were assessed by a recently described quantita-
tive method based on a digital analysis package in Ima-
geScope [18]. Specifically, the Positive Pixel Count v9 
algorithm was used with parameters optimized for the 
quantification of brown (DAB) immunohistochemical 
staining. To account for differences in ROI size across 
postmortem cases, the specific staining is reported as the 
total positive pixels per  mm2 stained area. Microglia were 
counted by a quantitative semi-automated method using 
ImageJ Software (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA). Spe-
cifically, 3 × 1 mm2 square ROIs were randomly selected 
from each brain region. Image processing included the 
following steps: colour deconvolution, 8-bit conversion, 
background subtraction and noise reduction. The appro-
priate brightness threshold was manually determined to 
create an overlay mask. The particle analysis plugin was 
used to count the number of activated microglia per 
 mm2. Size settings were optimized to primarily include 
enlarged amoeboid (activated microglia) and not small, 
ramified cells. This was done by measuring the cell soma 
diameter of amoeboid microglia in several sections in 
different brain regions and then using this experimenter-
determined diameter in the particle analysis plugin to 
quantify cells of similar or larger cell soma size only. This 
algorithm was applied to all the images across all brain 
regions using the Multiple Image Processor plugin and 
the mean of the 3× ROIs was used for statistical analysis. 
The same methodology was used for the quantification 
of HLA-DR+ and  Iba1+ activated microglia. Astroglial 
quantification was done by a semi-automated method 
using ImageJ Software. The total GFAP stained area was 
measured in 3 × 1  mm2 square ROIs per brain region 
and the mean was used for statistical analysis. Finally, 
the number of parenchymal but not perivascular  CD4+ 
and  CD8+ T lymphocytes was manually counted in the 
entire section of the substantia nigra and the amygdala. 
Infiltrating lymphocytes were expressed as the number of 
cells per  mm2.
RNA extraction from frozen postmortem brain
Frozen tissue samples from the substantia nigra, amyg-
dala, hippocampus, and frontal cortex were used for 
mRNA extraction. 20–40  mg of tissue were homog-
enized with Qiazol Lysis Reagent. RNA was then puri-
fied using the RNeasy Plus Universal Mini Kit according 
to the manufacturer’s instructions. RNA concentration 
was measured using a NanoDrop spectrophotometer. 
RNA integrity was determined by Agilent 2100 Bioana-
lyzer using Agilent RNA 6000 Nano Chips according to 
the manufacturer’s instructions. RNA samples with RIN 
numbers ≤ 5 were not used for further analysis. 300  ng 
of total RNA was converted to cDNA using the Super-
Script™ III First-Strand Synthesis SuperMix for qRT-PCR 
as per the manufacturer’s instructions.
Real‑time quantitative PCR
For each cDNA sample, the 20 µl reaction mixture con-
sisted of 10  µl of TaqMan Gene Expression Master-
mix (Thermo Fisher Scientific #4369510), 1  µl of the 
appropriate TaqMan primer/probe, 4  µl DNase free 
 H2O and 5  µl cDNA. A non-template sample (contain-
ing TaqMan primer/probe, TaqMan master mix and 
DNase free  H2O without cDNA) was used as a negative 
control. The following TaqMan (Thermo Fisher Scien-
tific) primer/probes were used: TLR2 (Hs02621280_s1), 
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TLR4 (Hs00152939_m1), TNFα (Hs00174128_m1), IL-1β 
(Hs01555410_m1), IL6 (Hs00174131_m1), IL8 (CXCL8) 
(Hs00174103_m1), and the housekeeping reference genes 
CYC1 (Hs00357717_m1), UBE2D2 (Hs00366152_m1) 
and GAPDH (Hs04420697_g1). Real-time amplifications 
were run in triplicates in a QuantStudio™ 12 K Flex Real-
Time PCR System (Applied Biosystems). The reaction 
mixtures were incubated at 50 °C for 2 min and 95 °C for 
10 min followed by 40 cycles at 95 °C for 10 s, and 60 °C 
for 1  min. The expression of the target genes  (CT) was 
normalized by subtracting the mean  CT of three house-
keeping reference genes (CYC1, UBE2D2 and GAPDH) 
giving the ΔCT for each sample. Statistical analysis was 
done on the ΔCT values as recommended by Yuan et al. 
[78] using two-tailed unpaired t-tests. For the graphical 
representation of the fold-change, the Livak method was 
used [49]. Briefly, the mean ∆CT of the control group was 
subtracted from the ∆CT of each sample to get the ∆∆CT. 
Finally, the formula  2−∆∆CT was used to extrapolate the 
fold-change. Fold-change is 1 for the control group (no 
change). For the PD group, fold-change > 1 indicates 
increased gene expression, whereas < 1 denotes decreased 
expression compared to the control group.
Statistical Analysis
The Shapiro–Wilk normality test was used to assess 
the distribution of variables. Accordingly, comparisons 
between control, PDND and PDD groups, were per-
formed either with a one-way ANOVA or a Kruskal–
Wallis test (for parametric and nonparametric variables, 
respectively), whilst correcting for multiple comparisons 
with the appropriate post hoc test. Comparisons between 
two groups were made with an unpaired two-tailed t test 
or by Mann-Whitey U test (for parametric and nonpara-
metric variables, respectively). Categorical variables were 
compared using a χ2 test.
Spearman’s rank-order correlation was used to assess 
correlations between neuropathological variables within 
specific regions. The association of pathological variables 
with cognitive decline during life (change in MMSE per 
year) was first assessed by Spearman’s rank-order corre-
lation. Pathological variables found to be associated with 
cognitive decline (p < 0.05) were then entered into a uni-
variate linear regression analysis, with rate of cognitive 
decline as the dependent variable, whilst correcting for 
age at death and disease duration. All correlative analy-
ses (between pathological, immune, and clinical markers) 
were exploratory and so formal correction for multiple 
testing was not applied.
IBM SPSS Statistics and GraphPad Prism were used for 
statistical analysis. Graphs were generated using Graph-
Pad Prism. A p value < 0.05 was defined as statistically 




Demographic and clinical characteristics of PD patients 
(n = 28) and controls (n = 14) are summarized in Table 1. 
11 PD patients developed dementia during life (PDD), 
whilst 17 had remained cognitively intact (PDND). The 
mean duration of dementia from onset to death was 
4.7 (± 2.9) years. Controls, PDND and PDD cases were 
matched for age, sex, and postmortem interval. For 5 of 
the PD cases, clinical data was only available for a single 
visit to the clinic. Those cases were excluded from the 
Table 1 Control and PD case demographics
Continuous variables were compared using One-way ANOVA (between Control, PDND and PDD) or Mann–Whitney U test (between PDND and PDD). Categorical 
variables (sex) were compared using the χ2 test. UPDRS Unified Parkinson’s Disease Rating Scale, MMSE Mini-Mental State Examination, PDND Parkinson’s disease no 
dementia, PDD Parkinson’s disease dementia. The values represent the mean (± SD)
*p < 0.05, ****p < 0.0001
Control PDND PDD p value
N 14 17 11 –
Postmortem interval (h) 64.1 (± 38.3) 58.8 (± 28.1) 61.5 (± 32.7) 0.903
Sex: % Male 64.3% 51.9% 90.9% 0.112
Age at death 79.8 (± 5.9) 79.0 (± 8.1) 81.8 (± 6.4) 0.573
Age at diagnosis – 66.9 (± 11.1) 67.9 (± 9.7) 0.803
Disease duration at death (yr) – 12.1 (± 4.8) 13.9 (± 6.4) 0.396
Interval from last assessment to death (yr) – 4.2 (± 3.3) 3.9 (± 4.1) 0.749
Last Hoehn and Yahr score – 2.6 (± 0.7) 2.9 (± 0.8) 0.693
Last UPDRS motor (on medication) – 30.6 (± 15.0) 39.3 (± 9.9) 0.117
Last UPDRS total (on medication) – 50.2 (± 21.3) 69.8 (± 16.9) 0.021*
Last MMSE – 28.7 (± 1.2) 20.6 (± 5.1) < 0.0001****
Change in MMSE per year – 0.21 (± 0.64) − 1.46 (± 1.34) < 0.0001****
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“interval from last assessment to death” and “change per 
year” analysis.
There was no difference in disease duration between 
the PDND and PDD groups. Total UPDRS at last assess-
ment was significantly higher in PDD compared to 
PDND cases (p = 0.021) as anticipated, but PDND and 
PDD groups were matched in terms of motor severity 
(UPDRS-III) at last assessment. PDD cases had signifi-
cantly lower MMSE scores at their last clinic visit prior 
to death, compared to PDND cases (p < 0.0001), as well 
as a significantly greater decline in MMSE scores per year 
(p < 0.0001).
Cause of death was also interrogated in the controls 
and PD cases (Fig. 1). The most frequent primary cause 
of death in the control group was cancer (43%) followed 
by cardiovascular conditions (29%). In the PD group, 
death was predominantly due to respiratory infection 
(32%; mainly bronchopneumonia) and cardiovascular 
disease (18%), with cancer and Parkinson’s disease being 
the third most common causes (11% each). Dementia was 
recorded as the primary cause of death in 7% of PD cases.
Increased cortical α‑synuclein pathology, but not tau 
or amyloid‑β in PDD compared to PDND brains
Examination of the substantia nigra confirmed marked 
loss of pigmented cells and the presence of Lewy bod-
ies and Lewy neurites in the remaining pigmented cells 
in all PD cases, but not in any of the controls. Formal 
quantification of Lewy body counts in this region was 
of little value as they were confounded by cell death. No 
neurofibrillary tau tangles or amyloid-β plaques were 
identified in the substantia nigra in either controls or 
PD cases. The extent of α-synuclein, tau and amyloid-β 
pathology was quantitatively measured in a further 
six brain regions, namely the hippocampus, amygdala, 
entorhinal, occipitotemporal, prefrontal and posterior 
parietal cortices.
Comparison of α-synuclein pathology was made only 
between PDND and PDD cases but not with controls 
due to the complete absence of Lewy bodies and neu-
rites in the latter (Fig.  2a). α-Synuclein pathology was 
greater in PDD compared to PDND across multiple 
brain regions, with comparisons reaching significance 
(p < 0.05) in the hippocampus, entorhinal, and occipito-
temporal cortex. There were no statistically significant 
differences in tau or amyloid-β pathology in any brain 
regions between the three groups (Fig. 2b, c).
Increased astrogliosis but not microglial activation 
in the PD substantia nigra
In the substantia nigra, quantification of the number 
of enlarged amoeboid HLA-DR+ microglial cells (acti-
vated) revealed no significant difference between con-
trols, PDND and PDD brains (Fig.  3a, b). Given that 
this finding contradicts previous reports of an increase 
in activated microglia in the nigra in PD, we performed 
additional staining in this region using the microglial 
marker Iba1, which confirmed similar results (Supple-
mentary Figure  1). Astrogliosis  (GFAP+ stained area) 
was increased in PDND brains compared to controls 
(Kruskal–Wallis with Dunn’s multiple comparisons 
test, p = 0.024; Control vs PDND p = 0.019) (Fig. 3c, d). 
This suggests increased astrocytic scarring in this brain 




























Fig. 1 Primary cause of death in controls and Parkinson’s disease cases. Among those dying of cancer, primary sites were the oesophagus, 
pancreas, colon, liver, lung, skin, breast and endometrium. Respiratory infections included bronchopneumonia, aspiration sepsis and lower 
respiratory tract infection, while other infections were urinary sepsis and Staphylococcal septicaemia. Cardiovascular causes of death were acute 
myocardial infarction, ischaemic heart disease, cardiac arrest, pulmonary embolism and ruptured aortic aneurysm. “Other” in the control group 
included old age and multiple organ failure and in the PD group, chronic obstructive pulmonary disease, and acute respiratory failure
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Microglial activation is increased in the amygdala of PDD 
cases
Quantification of microglial activation and astrogliosis 
was performed in six additional brain regions, namely, 
the amygdala, hippocampus, entorhinal, occipito-
temporal, prefrontal and posterior parietal cortex. 
Activated microglia counts in the amygdala were sig-
nificantly higher in PDD cases compared to controls 
(Kruskal–Wallis with Dunn’s multiple comparisons 
test, p = 0.039; Control vs PDD p = 0.046) (Fig.  4a, c). 
The number of activated microglia in the hippocam-









































































Fig. 2 Quantification of α‑synuclein, tau and amyloid‑β pathology in multiple brain regions. a There was in increase in α‑synuclein pathology 
in PDD compared to PDND cases in the hippocampus (Mann–Whitney U test, p = 0.015), entorhinal (Mann–Whitney U test, p = 0.015), and 
occipitotemporal cortex (Unpaired t test with Welch’s correction, p = 0.037). b There was no difference in tau pathology between groups in any 
region (Kruskal–Wallis test with Dunn’s correction for multiple comparisons, p > 0.05). c There were no between‑group differences in amyloid‑β 
pathology (Kruskal–Wallis test with Dunn’s correction for multiple comparisons, p > 0.05). AMG: Control n = 10, PDND n = 13, PDD n = 11, HIPP/
ERC/OTC: Control n = 8, PDND n = 13, PDD n = 10, PFC: Control n = 13, PDND n = 15, PDD n = 7, PPC: Control n = 13, PDND n = 17, PDD n = 11. 
PDND Parkinson’s disease no dementia, PDD Parkinson’s disease dementia, AMG amygdala, HIPP Hippocampus, ERC entorhinal cortex, OTC 
occipitotemporal cortex, PFC prefrontal cortex, PPC posterior parietal cortex. *p < 0.05
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but this did not withstand multiple comparisons cor-
rection. The number of activated microglia did not 
differ between groups in the remaining brain regions 
(Fig. 4c). Astrogliosis did not differ between controls, 
PDND and PDD cases in any brain region (Fig. 4b, d).
Increased T lymphocyte infiltration in PDND and PDD 
brains compared to controls
Initial investigations in the substantia nigra in a sub-
set of brains indicated a higher number of parenchyma 
infiltrating  CD3+ T cells per  mm2 in PD versus controls 
(p = 0.038). (Supplementary Figure 2). Parenchyma-infil-
trating  CD3+ T cells were also observed in the amyg-
dala in both PD cases and controls, but these cells were 
extremely sparse or absent in the hippocampus and the 
cortical brain regions we investigated. Therefore, the sub-
stantia nigra and the amygdala were further examined 
quantitatively for the presence of  CD4+ and  CD8+ T 
lymphocyte infiltration. Representative images of  CD4+ 
and  CD8+ immunostaining in the substantia nigra and 
amygdala of a control and Parkinson’s case are shown in 
Fig. 5a and c. The percentage of postmortem cases with 
0–10, or more than 10 infiltrating cells in the entire sec-
tion is illustrated in Fig. 5b, d, f, and h.
In the substantia nigra only 17% of controls showed 
significant  CD4+ lymphocyte infiltration (> 10 cells) com-
pared to 44% of PDND and 78% of PDD cases (χ2 = 75.15, 
p < 0.0001) (Fig.  5b). Quantification of parenchyma-
infiltrating lymphocytes per  mm2 revealed a significant 
increase in the number of  CD4+ T cells in the substan-
tia nigra in PDD > PDND > controls (p = 0.016; Control 
vs PDD p = 0.014) (Fig. 5i). A larger proportion of PDD 
cases (80%) had more than 10  CD8+ T  lymphocytes in 
the substantia nigra compared to PDND cases (69%) and 
controls (58%) (χ2 = 11.31, p = 0.0035) (Fig. 5d). However, 
there was no difference in the number of  CD8+ T  cells 



































































Fig. 3 Microglial activation and astrogliosis in the substantia nigra. a Representative image of HLA‑DR+ microglia in the substantia nigra of a 
control (left) and a Parkinson’s brain (right). The dark brown pigmented cells are neuromelanin‑containing dopaminergic neurons. b Quantification 
of the total activated (enlarged amoeboid) microglia per  mm2 (Kruskal–Wallis with Dunn’s multiple comparisons test, p = 0.646). c Representative 
image of astrocytic GFAP immunostaining in the substantia nigra of a control (left) and a Parkinson’s brain (right). d Quantification of the total 
GFAP‑stained area per  mm2 (Kruskal–Wallis with Dunn’s multiple comparisons test, p = 0.024; Control vs PDND p = 0.019). Control n = 12, PDND 
n = 16, PDD n = 10. PDND Parkinson’s disease no dementia, PDD Parkinson’s disease dementia. Scale bar: 100 μm. *p < 0.05
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comparisons (p = 0.105) (Fig.  5i). In the amygdala, only 
10% of controls showed marked  CD4+ T  lymphocyte 
infiltration (> 10 cells), as compared to 50% of PDND 
and 33% of PDD cases (χ2 = 37.68, p < 0.0001) (Fig.  5d). 
The number of  CD4+ T cells per  mm2, however, was not 
significantly different between the three groups after cor-
recting for multiple comparisons (p = 0.081) (Fig. 5i). The 
number of infiltrating  CD8+ T lymphocytes in the amyg-
dala was comparable across groups (p = 0.434) (Fig. 5i).
Pro‑inflammatory cytokine IL‑1β expression is upregulated 
in the substantia nigra and frontal cortex of PD brains
Quantitative real-time PCR with primers for TNFα, 
IL-1β, IL6, and IL8 was performed in four brain regions 
(substantia nigra, amygdala, hippocampus, and frontal 
cortex). Due to the limited availability of frozen brain 
tissue, PDD and PD cases were collapsed into a single 
group for comparison with controls. In the substantia 
nigra and frontal cortex, there was a significant increase 
in the expression of the pro-inflammatory cytokine IL-1β 
in PD compared to controls (p < 0.05) (Fig. 6a and d). In 
the amygdala and hippocampus there were no between-
group differences in cytokine expression (Fig. 6b, c).
TLR4 expression is upregulated in the substantia nigra, 
amygdala and frontal cortex of PD brains
Quantitative real-time PCR with primers for TLR2 and 
TLR4 was performed in four brain regions (substantia 
nigra, amygdala, hippocampus, and frontal cortex). TLR2 
expression was similar in PD and controls across in  all 
four brain regions (Fig. 7). In contrast, TLR4 was signifi-
cantly upregulated in the substantia nigra (p = 0.006), the 
amygdala (p = 0.035) and the frontal cortex (p = 0.006) of 
PD cases compared to controls (Fig. 7).
Correlation between neuropathological and immune 
markers
Spearman’s rank-order correlation in PD cases between 
the pathological proteins in each brain region revealed 
a consistent association between α-synuclein and tau 
in all the examined brain regions, most strongly in the 
amygdala (Rho = 0.575, p = 0.003) and prefrontal cortex 
(Rho = 0.602, p = 0.003) (Table 2). There was also a corre-
lation between α-synuclein and amyloid-β in the occipi-
totemporal and posterior parietal cortices. No significant 
correlation was observed between tau and amyloid-β in 
any brain region.
In PDND and PDD cases, Spearman’s rank-order 
correlation was performed between all three patho-
logical proteins and the number of activated microglia 
in each brain region (Supplementary Table  1). In the 
amygdala, HLA-DR+ microglial count significantly 
correlated with α-synuclein (Rho = 0.448; p = 0.028). 
In the posterior parietal cortex, the number of acti-
vated microglia was significantly associated with tau 
pathology (Rho = 0.471; p = 0.013). No correla-
tion between activated microglia and amyloid-β was 
observed in any region.
In the amygdala, Spearman’s rank-order correlation 
also revealed a significant correlation between  CD4+ 
T lymphocytes with both α-synuclein (Rho = 0.443; 
p = 0.034) and tau pathology (Rho = 0.420; p = 0.046), 
as well as a correlation between  CD8+ T lymphocytes 
and tau pathology (Rho = 0.569; p = 0.006) (Supple-
mentary Table  2). In this brain region, the number of 
infiltrating  CD4+, but not  CD8+ T lymphocytes was 
correlated with the number of activated microglia 
(Spearman’s Rho = 0.525; p = 0.01).
Association between neuropathology and cognitive 
decline
We sought to identify which pathological marker was 
the best correlate to longitudinal cognitive decline in 
life (measured by the MMSE). Only cases with clini-
cal data collected up to and including 3  years prior to 
death were included in this analysis (n = 13). Four vari-
ables correlated significantly with MMSE change per 
year using Spearman’s Rank-Order Correlation (i.e., 
α-synuclein pathology in the hippocampus, entorhinal, 
occipitotemporal and prefrontal cortices). Univariate 
linear regression, correcting for age at death and disease 
duration, confirmed a significant association between 
MMSE change per year and α-synuclein pathology in 
the hippocampus  (F(3,9) = 14.73, p = 0.001), entorhinal 
(See figure on previous page.)
Fig. 4 Microglial activation and astrogliosis in extra‑nigral brain regions. a Representative image of HLA‑DR+ microglia in the amygdala of a 
control (left) and a Parkinson’s brain (right). b Representative image of astrocytic GFAP immunostaining in the amygdala of a control (left) and a 
Parkinson’s brain (right). c Quantification of activated (enlarged amoeboid) microglia per  mm2. There was a significant increase in the number of 
activated microglia in the amygdala of PDD cases compared to controls (Kruskal–Wallis with Dunn’s multiple comparisons test, p = 0.039; Control 
vs PDD p = 0.045). d Quantification of the total GFAP‑stained area per  mm2 (Kruskal–Wallis with Dunn’s multiple comparisons test, p > 0.05). AMG: 
Control n = 10, PDND n = 13, PDD n = 11; HIPP/ERC/OTC: Control n = 8, PDND n = 13, PDD n = 10; PFC: Control n = 13, PDND n = 15, PDD n = 7. 
PPC: Control n = 13, PDND n = 17, PDD n = 11. PDND Parkinson’s disease no dementia, PDD Parkinson’s disease dementia, AMG amygdala, HIPP 
hippocampus, ERC entorhinal cortex, OTC occipitotemporal cortex, PFC prefrontal cortex, PPC posterior parietal cortex. Scale bar: 100 μm. *p < 0.05
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 (F(3,9) = 33.98, p < 0.0001), occipitotemporal  (F(3,9) = 7.80, 
p = 0.007), and prefrontal cortex  (F(3,9) = 12.51, p = 0.002) 
(Table 3).
Discussion
This study provides novel insights into the neuropatho-
logical substrates of cognitive decline in PD through 
investigating, for the first time, the nature and dis-
tribution of neuroinflammatory change in PD cases 
with or without dementia and correlating this with 
protein pathology. We confirm previous findings that 
α-synuclein pathology correlates with the rate of cog-
nitive decline in PD, whilst the levels of Alzheimer’s 
disease-type pathology were found to be comparable 
across groups. Neuroinflammatory change in PDD cases 
was most pronounced in the amygdala, a limbic region 
heavily implicated in emotion and cognition [61]. Spe-
cifically, we observed increased microglial activation 
in the amygdala in PDD  brains compared to controls 
and found evidence of  CD4+ T cell infiltration into this 
region in all PD dementia cases. Furthermore, micro-
glial activation,  CD4+ T cell infiltration and α-synuclein 
pathology were correlated in this region, implicating 
an α-synuclein-driven neuroinflammatory response in 
the amygdala in PD dementia. We explored the expres-
sion of pro-inflammatory cytokines as well as TLR2 and 
TLR4 in several extra-nigrostriatal regions and observed 
elevated expression of TLR4 in the amygdala, frontal 
cortex, and substantia nigra, accompanied by elevated 
levels of the downstream inflammatory cytokine IL-1β. 
Taken together, our observations are consistent with the 
hypothesis that α-synuclein drives a neuroinflamma-
tory response in PD through the activation of microglial 
TLR4 [46] and suggest a contributory role for peripheral 
T lymphocytes.
Our results show a significantly higher burden of 
α-synuclein pathology in PDD compared to PDND cases 
across multiple brain regions. This is consistent with pre-
vious findings of increased α-synuclein burden in PD 
dementia. Compta et  al. using both a semi-quantitative 
Lewy body scoring system and quantification of Lewy 
body density per  mm2 found a significantly elevated bur-
den in PDD (n = 29) compared to PDND brains (n = 27), 
particularly in the frontal, temporal, cingulate and 
entorhinal cortex [9]. A second large autopsy study in 92 
PDD and 48 PDND brains using traditional scoring pro-
tocols reported similar results in the same brain regions 
[38]. These findings were further validated in another 
large study with 55 PDD and 49 PDND cases [64]. Pre-
vious volumetric MRI studies have also implicated the 
amygdala in PD dementia showing significant atrophy 
of this region in demented PD patients compared to 
healthy controls but not in cognitively intact PD patients 
compared to controls, thus implicating the amygdala in 
cognitive decline in PD [40]. A limited number of stud-
ies have also addressed the role of abnormalities in the 
amygdala in relation to other non-motor symptoms of 
PD. On a functional level, a magnetic resonance imag-
ing (MRI) study revealed that in the absence of structural 
alterations, there were abnormally high levels of activity 
in the amygdala of depressed PD patients compared to 
patients without depression and to controls. This height-
ened activity was found to be positively correlated with 
clinical scores of depression. Functional connectivity 
between the amygdala and fronto-parietal cortices was 
also found to be reduced, specifically in the patients suf-
fering from depression [32]. Furthermore, an early clin-
icopathological study showed that PD patients suffering 
from hallucinations had nearly double Lewy body density 
in the basolateral amygdala compared to patients that did 
not experience them [28]. Amygdala abnormalities have 
also been linked to cognitive decline in Alzheimer’s dis-
ease. Similar to PD, atrophy of the amygdala was shown 
to be substantial in two large independent cohorts of 
mild Alzheimer’s disease. The magnitude of atrophy 
was strongly predictive of cognitive decline as shown by 
a robust correlation with MMSE scores [62]. The role 
of amygdala dysfunction in PD dementia has not been 
extensively studied and based on our present findings 
may warrant further investigation.
Fig. 5 CD4+ and  CD8+ T lymphocytes in the substantia nigra and the amygdala. a, c Representative image of parenchyma infiltrating  CD4+ 
and  CD8+ T lymphocytes in the substantia nigra of a control (left) and a Parkinson’s brain (right). The dark brown pigment is neuromelanin 
within dopaminergic neurons; the smaller  CD4+ and  CD8+ T cells are shown in the higher magnification inserts indicated by black squares. b, d 
Percentage of controls, PDND and PDD cases that show 0–10 or more than 10 infiltrating  CD4+ (χ2 = 75.15, p < 0.0001) or  CD8+ T cells (χ2 = 11.31, 
p = 0.0035) in the entire nigral section e, g Representative image of parenchyma infiltrating  CD4+ and  CD8+ T lymphocytes in the amygdala of a 
control (left) and a Parkinson’s brain (right).  CD4+ and  CD8+ T cells are shown in the higher magnification inserts indicated by black squares. f, h 
Percentage of controls, PDND and PDD cases that show 0–10 or more than 10 infiltrating  CD4+ (χ2 = 37.68, p < 0.0001) or  CD8+  T cells (χ2 = 3.92, 
p = 0.141) in the entire amygdala section. i Quantification of parenchymal  CD4+ (p = 0.023, Control vs PDD p = 0.018) and  CD8+ T lymphocytes 
(p = 0.102) per  mm2 in the substantia nigra. Control n = 12, PDND n = 16, PDD n = 10. Quantification of parenchymal  CD4+ (p = 0.081) and  CD8+ T 
lymphocytes (p = 0.434) per  mm2 in the amygdala. Control n = 10, PDND n = 12, PDD n = 11. Kruskal–Wallis with Dunn’s multiple comparisons test. 
PDND Parkinson’s disease no dementia, PDD Parkinson’s disease dementia. Scale bar: 100 μm. Scale bar (insert): 20 μm. *p < 0.05
(See figure on previous page.)
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Notably, we did not observe any significant differ-
ences in tau pathology between PDND and PDD cases. 
In agreement, semi-quantitative scoring in  a large post-
mortem study revealed similar levels or neurofibrillary 
tau tangles in the temporal, mid-frontal, and parietal 
cortex of PDND and PDD cases [38]. Tau Braak staging, 
however, has shown inconsistent results across studies; 
whilst Horvath et  al. found the overall tau Braak stage 
to be significantly higher in demented compared to 
non-demented PD cases [30], Ruffmann and colleagues 
did not find differences between the groups, with 84% 
of all cases having only mild tau pathology (Braak stage 
0–2) [64]. We did not observe significant differences in 
amyloid-β pathology between controls, PDND, and PDD 
cases. In contrast, previous studies have reported higher 
amyloid-β scores in the hippocampus, striatum, entorhi-
nal and frontal cortex of demented compared to non-
demented PD brains [64]. The total amyloid-β plaque 






































































































Fig. 6 Expression of inflammatory cytokines in PD and control brains. Fold change in cytokine gene expression in the PD group relative to the 
control group. The dotted line marks the control group (Fold change = 1 indicates same levels of gene expression as in controls. Fold‑change > 1 
indicates increased gene expression, while < 1 denotes decreased expression compared to controls). a In the substantia nigra, IL‑1β was significantly 
upregulated in the PD group compared to controls (two‑tailed unpaired t‑test, t(17) = 2.263, p = 0.037; Control n = 5, PD n = 14). b, c No differences 
in cytokine expression were observed in the amygdala (two‑tailed unpaired t‑test, p > 0.05; Control = 5, PD = 8) and the hippocampus (two‑tailed 
unpaired t‑test, p > 0.05; Control n = 5, PD n = 13). d In the frontal cortex of PD cases, IL‑1β was more highly expressed compared to controls 
(two‑tailed unpaired t‑test, t(15) = 2.278, p = 0.038; Control n = 6, PD n = 11). Fold change = 2−∆∆CT. *p < 0.05
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score, total amyloid angiopathy in the cortex [9], and the 
amyloid-β Thal phases [30, 72] have also been reported to 
be significantly higher in PDD compared to PDND. This 
discrepancy of our results with previous studies may be 
due to the difference in brain regions under investigation 
and the smaller sample size used in our study. Indeed, 
we observed a trend for increased amyloid-β deposition 
in the PDD cases compared to both PDND and controls, 
however this was not significant after correcting for mul-
tiple comparisons.
We hypothesized that neuroinflammation might be 
an additional neuropathological substrate contribut-
ing to dementia in PD. PET neuroimaging studies using 
 [11C]PK11195, a ligand for TSPO which is upregulated 
on activated microglia, have similarly suggested that 


















































































Fig. 7 Expression of TLR2 and TLR4 in PD and control brains. Fold change in TLR2 and TLR4 gene expression in PD compared to controls. The dotted 
line marks the control group (Fold change = 1 indicates same levels of gene expression as in controls. Fold‑change > 1 indicates increased gene 
expression, while < 1 denotes decreased expression compared to controls). a In the substantia nigra, TLR4 expression was significantly higher in the 
PD group compared to controls (two‑tailed unpaired t‑test, t(18) = 3.09 p = 0.006; Control n = 6, PD n = 14) b TLR4 expression was also elevated in 
the amygdala (two‑tailed unpaired t‑test, t(11) = 2.41, p = 0.035; Control n = 5, PD n = 8). c No differences in either TLR2 or TLR4 gene expression 
were observed in the hippocampus (two‑tailed unpaired t‑test p > 0.05; Control n = 7, PD n = 13). d There was a significant increase in TLR4 
expression in the frontal cortex of PD cases compared to controls (two‑tailed unpaired t‑test, t(17) = 3.14, p = 0.006; Control n = 7, PD n = 12). Fold 
change = 2−∆∆CT. *p < 0.05, **p < 0.01
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and colleagues demonstrated increased tracer uptake in 
multiple brain regions in demented PD patients com-
pared to controls, which was much more widespread 
than in non-demented PD patients versus controls 
[20]. We have previously shown that PD patients with 
a higher risk of progressing to dementia have increased 
activation of the innate immune system, including an 
increase in classical (inflammatory) monocytes, and 
increased monocyte expression of both TLR2 and 
TLR4 compared to patients at low risk of dementia 
[74]. Furthermore, we found that a pro-inflammatory 
cytokine profile in the serum in newly-diagnosed PD 
patients was associated with faster UPDRS-III pro-
gression and more impaired cognitive function over 
3  years of follow-up [77]. However, the contribution 
of neuroinflammation to PDD has not previously been 
explored at postmortem. Our novel data show an 
increase in activated HLA-DR+ microglia in the amyg-
dala of PDD cases. In a previous study Imamura et  al. 
showed increased numbers of HLA-DR+ microglia in 
the hippocampus, transentorhinal, cingulate and tem-
poral cortex in a relatively small number of PD (n = 12) 
and control (n = 4) autopsy cases, though in this study 
no distinction was made between demented and non-
demented PD brains [36]. The lack of a PD versus con-
trol difference in activated microglia in these regions in 
our study may relate to the characteristics of the con-
trol population used. We opted to select typical elderly 
controls on the basis of having no neurological or cog-
nitive symptoms during life and not on the basis of an 
absence of tau or amyloid-β pathology in the brain. 
In contrast, other authors typically select “supranor-
mal” controls with no neurofibrillary tau tangles or 
amyloid-β plaques. Such controls are not representative 
of the normal neurologically intact aged population; 
indeed it has been repeatedly demonstrated that mis-
folded tau and amyloid-β accumulation occurs during 
ageing in the absence of neurodegenerative disease [3, 
11, 50, 63, 65]. Our controls had a degree of amyloid-β 
and tau pathology and such misfolded protein deposi-
tion may trigger low level microglial activation. This 
could explain the contradictory findings in our study 
compared to previous work [36].
Surprisingly, we did not find a difference in HLA-
DR+ microglia count in the substantia nigra of PD cases 
(either PDND or PDD) compared to controls. This is in 
contrast to the seminal study by McGeer et  al. in 1988 
who first reported an increase in HLA-DR+ microglia in 
this region of PD cases compared to controls [52]. Similar 
findings have been reported by a subsequent study show-
ing an increase in both amoeboid  CD68+ microglia as 
well as  Iba1+ microglia in the postmortem PD nigra [15]. 
These inconsistencies with our findings may be partly 
explained by methodological differences in the identifica-
tion of activated microglia as discussed below, as well as 
differences in the selection of control populations.  [11C]
PK11195 PET neuroimaging studies have also shown 
conflicting data. Ouchi et al. found increased binding in 
the midbrain of newly diagnosed PD patients [59], whilst 
Gerhard et al. did not find a difference in the substantia 
nigra of patients compared to controls [25]. Additional 
studies are needed to ascertain the extent of microglial 
activation in the substantia nigra and at which stage of 
the disease this is more prominent.
Although we did not observe an increase in number of 
activated microglia in the nigra, we did observe increased 
infiltration of peripheral T lymphocytes in this region 
in PDD and PDND cases, as well as elevated IL-1β lev-
els, providing alternative evidence of immune activation 
Table 2 Spearman’s rank-order correlation between 
pathological proteins in PD cases
Rho Spearman’s correlation coefficient
*p < 0.05; **p < 0.01
Region Tau Amyloid‑β
Rho p value Rho p value
Amygdala (n = 24) α‑synuclein 0.575 0.003** 0.219 0.304
Hippocampus (n = 22) 0.431 0.040* 0.034 0.879
Entorhinal cortex (n = 23) 0.468 0.024* 0.257 0.248
Occipitotemporal cortex 
(n = 22)
0.535 0.010* 0.438 0.047*
Prefrontal cortex (n = 22) 0.602 0.003** 0.385 0.077
Posterior parietal cortex 
(n = 28)
0.354 0.070* 0.413 0.029*
Table 3 Univariate linear regression of MMSE change per year with correction for age at death and disease duration
MMSE Mini-mental state examination
Variable Standardized beta coefficient Adjusted  R2 p value
α‑Synuclein in the hippocampus − 0.914 0.774 0.001
α‑Synuclein in the entorhinal cortex − 0.972 0.892 < 0.0001
α‑Synuclein in the occipitotemporal cortex − 0.868 0.630 0.007
α‑Synuclein in the prefrontal cortex − 0.958 0.738 0.002
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in this region. Brochard et al. have previously shown an 
increased number of both  CD4+ and  CD8+ T lympho-
cytes in the substantia nigra of PD cases compared to 
controls, especially in the vicinity of dopaminergic neu-
rons [6]. Additionally, recent work by Sommer et al. using 
CD3, a pan-T lymphocyte marker, revealed an increase 
in total  CD3+ T lymphocytes (including parenchymal 
and perivascular cells) in the substantia nigra of PD cases 
compared to controls [68]. Our results corroborate these 
earlier findings and we also show that this increase is pre-
dominantly seen in PD dementia cases compared to con-
trols. Furthermore, we observed a similar non-significant 
trend in the amygdala, particularly in the numbers of 
 CD4+ but not of  CD8+ T  lymphocytes, and found that 
significant  CD4+ T  lymphocyte infiltration (more than 
10 cells) into the amygdala was more common in PDND 
and PDD (50% and 33% of cases) compared to controls 
(10% of cases). Infiltration of T lymphocytes in the brain 
parenchyma has also been observed in other synucle-
inopathies. In particular,  CD4+ but not  CD8+ or B lym-
phocytes were found to be increased in the frontal cortex 
and hippocampus of cases with dementia with Lewy 
bodies (DLB) compared to controls at postmortem [35]. 
A second recent study in DLB cases showed increased T 
lymphocyte infiltration in both the grey and white matter 
of the middle temporal gyrus, in the absence of promi-
nent microglial activation [2]. Similarly, in the substantia 
nigra of cases with multiple system atrophy compared 
to controls both  CD4+ and  CD8+ T lymphocytes were 
found to be increased [75]. The role of infiltrating T lym-
phocytes in PD is still unclear, however, ablation of  CD4+ 
T cells in an MPTP mouse model of PD was found to be 
neuroprotective [6]. In another set of experiments using 
an AAV-α-synuclein rat model of PD it was observed 
that T cell-deficient (athymic nude) mice were protected 
from dopaminergic neuron loss in the substantia nigra 
[70]. Taken together, this data suggests that these adap-
tive immune cells may have a cytotoxic effect in PD and 
related synucleinopathies. Furthermore, recent evidence 
from human studies suggests that α-synuclein epitopes 
are recognised by autoreactive  CD4+ T lymphocytes 
in PD [71], which may explain our observed a signifi-
cant correlation between  CD4+ T cells and α-synuclein 
pathology in the amygdala in our PD cases.
Both activated microglia and infiltrating lymphocytes 
may be exerting neurotoxic effects via the production of 
pro-inflammatory cytokines. In this study, we report for 
the first time an upregulation of the pro-inflammatory 
cytokine IL-1β in the frontal cortex of PD cases compared 
to controls. Gene expression of IL-1β was also increased 
in the PD substantia nigra, in line with previous evidence 
[55]. It should, however, be noted that caution is needed 
when interpreting these results, given that the control 
sample size available for gene expression analysis was 
small. Furthermore, bulk tissue was used in these experi-
ments with normalisation against housekeeping genes. 
Therefore, the reported gene expression findings have 
not been adjusted for potential differences in the ratio of 
neurons to glial cells which may occur due to increased 
neuron loss in certain regions in the PD cases com-
pared to controls. The expression of pro-inflammatory 
cytokines in postmortem PD has not been extensively 
investigated in the past. In fact, previously available data 
come primarily from early work by Mogi and colleagues 
who quantified the protein levels of several cytokines in 
the substantia nigra using enzyme-linked immunoassays. 
They reported higher levels of both IL-1β and IL6 [55], as 
well as elevated TNFα and IL2 in the substantia nigra of 
PD brains compared to controls [56, 57].
One likely pathway leading to upregulation and secre-
tion of pro-inflammatory cytokines is that mediated by 
Toll-like receptor activation. In  vitro experiments have 
shown that microglia can be directly activated by mis-
folded α-synuclein through both TLR2 [44] and TLR4 [22, 
66]. Increased protein levels of  TLR2 and TLR4 have pre-
viously been reported in the substantia nigra [15, 67], and 
the caudate/putamen of PD compared to control brains 
[16], and in addition, these receptors are upregulated in 
peripheral blood mononuclear cells of PD patients com-
pared to controls [16, 74]. Our work has now shown 
elevation of TLR4 expression in multiple brain regions 
including the substantia nigra, amygdala and frontal cor-
tex of PD cases compared to controls. Notably, in these 
same brain regions in PD, we also observed increased 
expression of IL-1β, a downstream product of the inflam-
masome pathway which is triggered by TLR4 activation. 
Interestingly, TLR2 and TLR4 have also been implicated 
in other proteinopathies, including Alzheimer’s [69] and 
Huntington’s disease [73] raising the possibility of a com-
mon pathogenic mechanism across several neurodegen-
erative diseases. The concomitant increase in the gene 
expression of TLR4 and IL-1β in the substantia nigra and 
the frontal cortex suggests an involvement of the NOD-
like receptor protein 3 (NLRP3) inflammasome in these 
regions, with TLR4 activation resulting in increased 
expression of pro-IL-1β as well as NLRP3 activation; in 
turn, NLRP3 inflammasome activation could be respon-
sible for the cleavage of pro-IL1β to the mature protein. 
This hypothesis is supported by recent data showing an 
upregulation of the protein levels of the NLRP3 adapter 
protein ASC (apoptosis-associated speck-like protein con-
taining a caspase recruitment domain) as well as cleaved 
caspase-1 in postmortem nigral samples of PD cases com-
pared to controls [26]. The same study also showed that 
inhibition of NLRP3 activation in a mouse model of PD 
(intrastriatal injection of α-synuclein pre-formed fibrils) 
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could effectively mitigate motor dysfunction as well as 
dopaminergic neuron loss. Nevertheless, future stud-
ies are necessary to determine whether NLPR3 inflam-
masome activation is also occurring in other extranigral 
regions, particularly in the amygdala and the frontal cor-
tex of PD cases versus controls.
In this study, we observed significant correlations 
between cortical α-synuclein Lewy pathology and the 
rate of cognitive decline during life. This finding cor-
roborates previous evidence showing a robust correla-
tion between cortical Lewy body burden and cognitive 
decline in PD using multivariate linear regression analy-
ses [1, 64]. Other investigators have used the presence 
of dementia as the primary outcome in a logistic regres-
sion model, showing that neocortical Lewy body burden 
is strongly associated with dementia in PD [30, 38]. In 
keeping with our findings that tau and amyloid-β pathol-
ogy did not differ between demented and non-demented 
PD cases, we did not find a correlation between either tau 
or amyloid-β in any of the examined brain regions and 
MMSE decline per year.
Although our data implicate neuroinflammation, par-
ticularly in the amygdala in PDD, we did not find a signif-
icant correlation between inflammatory changes in this 
region and cognitive decline during life. A previous study 
similarly found no correlation between HLA-DR+ micro-
glia in the substantia nigra and clinical parameters in PD, 
whilst the use of a different marker CD68 (indicative of 
microglial phagocytic activity) revealed a strong asso-
ciation between  CD68+ microglia and disease duration 
[12]. The method of characterizing activated microglia 
in postmortem brain may be critical to revealing clinico-
pathological correlations.
Indeed, a limitation of our study and a major chal-
lenge in postmortem brain studies overall is the defini-
tion of “activated microglia”. Here we have used enlarged 
and amoeboid morphology to quantify activated micro-
glia selectively. However, this is a subjective method 
and microglial morphology is not restricted into either 
ramified or amoeboid shapes but represents a con-
tinuum including a whole range of morphological phe-
notypes [7]. Another caveat in our analysis is that the 
immunostaining of microglia was performed on thin 
brain  sections   (10 µm). Previous studies assessing phe-
notypic differences to classify microglia have done so 
in sections  30–40  µm-thick [24, 48], with Kongsui and 
colleagues finding that the diameter of many micro-
glia ranges between 40 and 50  µm [45] suggesting that 
even thicker sections would be needed for morphologi-
cal studies. Furthermore, although microglia had been 
generally considered to be a functionally homogeneous 
population, comprehensive RNA sequencing studies 
have found evidence of different microglial subtypes with 
distinct function and have identified markers which can 
help distinguish between them. For instance, a recent sin-
gle-cell RNA sequencing study in postmortem brain tis-
sue from Alzheimer’s disease cases discovered a subtype 
of “disease-associated microglia” (DAM), with a unique 
transcriptional and functional profile, characterized by 
high phagocytic activity and upregulation of specific 
markers such as TREM2 [43]. Therefore, future work in 
postmortem brain could make use of additional markers 
such as P2RY12 and TMEM119 (homeostatic microglia) 
[4], and TREM2 (DAM) to better understand the role of 
microglia in PD. Future work could also utilise compre-
hensive genome-wide expression analyses which have 
become possible through the use of protocols to isolate 
microglia from human brain tissue [58] or by singe-cell 
RNA sequencing using bulk tissue, as has recently been 
done in Alzheimer’s disease postmortem brain [14].
Strengths of our study include our cohort of clini-
cally well-characterised cases enabling the correlation 
between the pathological markers with the clinical course 
of the disease during life, as well as the use of controls 
who are representative of the typical aged population as 
discussed earlier. Additionally, in this study we employed 
a digital image analysis approach to quantitatively evalu-
ate the severity of protein pathology in the postmortem 
brain. Traditional pathology is based on semiquantita-
tive scoring upon visual inspection [53, 54] and is a useful 
method of assessing the distribution and overall protein 
pathology burden but it is inevitably subject to inter-
rater variability and may also lack sensitivity particularly 
in identifying subtle differences in pathology severity. 
Digital quantification is a reliable alternative, useful for 
high throughput analysis, and can provide a more accu-
rate quantitative measure of pathology severity [18, 23]. 
The methodology used in the present study was based on 
work described by Dunn et al. who showed a strong cor-
relation between the automated analysis and the conven-
tional scoring methodology [18].
In summary, this study demonstrates that dementia 
in PD is associated with increased neuroinflammation 
in the substantia nigra and amygdala at postmortem, 
involving microglial activation and the infiltration of 
T lymphocytes. We also report an upregulation of the 
pro-inflammatory cytokine IL-1β and upstream TLR4 in 
both the substantia nigra and extra-nigrostriatal regions 
in PD. We have confirmed that limbic and neocortical 
α-synuclein is the most robust predictor for dementia in 
PD and identified a correlation between α-synuclein and 
neuroinflammation in the amygdala. Taken together, this 
data suggests that a combination of α-synuclein pathol-
ogy and inflammatory changes in the brain are critically 
involved in dementia in PD.
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Additional file 1: Fig. S1. Iba1+ activated microglia in the substan‑
tia nigra. (a) Representative image of  Iba1+ microglia in the substantia 
nigra of a control (left) and a Parkinson’s brain (right). The dark brown 
pigmented cells are neuromelanin‑containing dopaminergic neurons. (b) 
Quantification of the total activated (enlarged amoeboid) microglia per 
 mm2 (Kruskal–Wallis with Dunn’s multiple comparisons test, p = 0.269). 
Control n = 12, PDND n = 15, PDD n = 8. PDND: Parkinson’s disease no 
dementia, PDD: Parkinson’s disease dementia. Scale bar: 100 μm. *p < 0.05.
Additional file 2: Fig. S2. CD3+ T lymphocytes in the substantia nigra. 
(a) Representative image of parenchyma infiltrating  CD3+ T lymphocytes 
in the substantia nigra of a control (left) and a Parkinson’s brain (right). 
The dark brown pigment is neuromelanin within dopaminergic neurons; 
the smaller  CD3+ T cells are shown in the higher magnification inserts 
indicated by black squares. (b) Quantification of parenchymal  CD3+ T 
lymphocytes per  mm2 in the substantia nigra (Mann–Whitney U test, 
p = 0.038). Control n = 7, PD n = 16. Scale bar: 100 μm. Scale bar (insert): 
20 μm. *p < 0.05.
Additional file 3: Spearman’s rank‑order correlation between pathologi‑
cal proteins and activated microglia.
Additional file 4: Spearman’s rank‑order correlation between pathologi‑
cal proteins and infiltrating T lymphocytes in the amygdala.
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